US pharmaceutical company
US pharmaceutical company
Bristol Myers Squibb and A.C.Camargo Cancer Center signed BMS’s first oncology risk-sharing agreement in Brazil, covering first-line ipilimumab plus nivolumab in lung cancer, with results assessed within 90 days of …
ANVISA has approved serplulimab as the only anti-PD-1 authorized in Brazil for extensive-stage small cell lung cancer, giving Abbott a regulatory head start before larger checkpoint inhibitor rivals.
You must be logged in to post a comment.